TxCell Stock

Stocks

TXCL

FR0010127662

Biotechnology & Medical Research

Real-time 5-day change 1st Jan Change
- EUR -.--% Intraday chart for TxCell -.--% +67.53%
Manager TitleAgeSince
Chief Operating Officer 50 -
Corporate Officer/Principal - -
Corporate Officer/Principal - -
Director TitleAgeSince
Chairman - 2019-02-11
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 0
+4.16%+3.04%+49.37%+94.17% 74.16B
-0.37%-3.88%+19.75%+78.35% 57.39B
+1.63%+0.98%+3.83%+38.21% 47.64B
+0.50%+1.32%+344.62%+753.25% 44.29B
+3.05%-1.58%+28.78%+35.46% 42.5B
+1.00%+0.22%+5.17%+113.80% 40.71B
-0.54%+2.93%+9.31%+54.06% 30.97B
+1.56%+4.53%+31.34%+26.92% 28.53B
+0.76%-0.89%-7.44%-11.43% 24.34B
Average +1.15%-0.59%+53.86%+131.42% 43.39B
Weighted average by Cap. +1.52%-0.84%+58.06%+140.75%
Logo TxCell
TxCell is a biotechnology company which develops platforms for innovative customized cell immunotherapies from regulatory T cells (Treg) for the treatment of severe chronic inflammatory, autoimmune diseases and transplant rejection. TxCell is developing a platform for genetically modified T-cells, the CAR-Tregs. TxCell plans to release preclinical proof-of-concept data in 2017 and start a first clinical study by the end of 2018.
Employees
-
  1. Stock Market
  2. Stocks
  3. TXCL Stock